14.06.2019 • News

Wacker Opens Silicone Elastomer Plant in China

Wacker Opens Silicone Elastomer Plant in China (c) Wacker
Wacker Opens Silicone Elastomer Plant in China (c) Wacker

German chemical producer Wacker has inaugurated a new production line for silicone elastomers at its Zhangjiagang, China, site. The company said the “several thousand” t/y facility, which cost in the “lower double digit million range” will improve the availability of high consistency silicone rubber (HCR) in the Asia Pacific region.

With start-up of the new line, Paul Lindblad, president of Wacker Greater China, said the Munich-based company is significantly expanding its global production capacity for HCR. He added that the investment “shows our determination to further serve and develop local and regional market.” The expansion of the silicone elastomer plant is yet another example of the company’s ongoing investments into its Chinese facilities, he added.

Pointing to a “growing need” for silicone specialties and high quality silicone rubber, Christian Gimber, Wacker’s vice president of engineering silicones, said high consistency rubbers are expected to continue on their growth path, with demand for solid silicone elastomers rising quickly, especially in China. The country is the single largest market for silicone elastomers in the world.

Looking at technical specifications, Wacker said the new facility’s kneaders are currently the largest of their kind in the industry. The plant’s mixing and screening equipment, and the state-of-the-art waste treatment process are also “setting industry standards in terms of productivity and sustainability.”

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read